Market Views – Page 23 – media

Google-Backed FLX Bio Scores $60M Financing

FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small-molecule drugs to activate the immune system against cancer, today announced the completion of a $60 million Series C private financing. The financing included new investments from GV (formerly Google Ventures) and other undisclosed investors as well as existing investors including The Column Group, Kleiner Perkins, Topspin Partners and Celgene Corporation.
- Source: Flxbio
- 420
- December 27, 2017
Market Views oral small-molecule drugs
AZ and ICL link to research respiratory diseases

AstraZeneca and Imperial College London have announced plans to work together on investigating the scientific mechanisms and underlying drivers of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
- Source: pharmatimes
- 548
- December 27, 2017
asthma AstraZeneca COPD Market Views
Increased Demand for 3D Printed Medical Device Products

3D printed medical device products are very high-end devices that are engaged in the process of utilizing digital models to develop a three-dimensional object.In the healthcare industry, many academic institutes make use of this technology for patient-specific treatment.The key 3D printed medical devices companies are working on strategies that would increase their market share.
- Source: Ddu
- 742
- December 27, 2017
Market Views medical device products
Theranos gets $100 million in debt financing to carry it through 2018, with some caveats

Theranos has secured $100 million in debt financing. Yes, someone gave the blood testing company known for handing out questionable test results money.
- Source: Techcrunch
- 373
- December 26, 2017
blood testing debt financing Market Views
Janssen buys into Legend’s CART therapy

Janssen has entered into a global collaboration and license agreement with Legend Biotech USA and Legend Biotech Ireland to develop, manufacture and commercialise experimental CART-cell therapy LCAR-B38M.
- Source: Pharmatimes
- 412
- December 26, 2017
CAR-T therapy Company Insight Market Views
Roche and Ignyta Reach Definitive Merger Agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. The merger agreement has been unanimously approved by the boards of Ignyta and Roche.
- Source: Roche
- 527
- December 25, 2017
Ignyta Market Views Roche
3 Amazing Advances in Pharmaceutical Drugs in 2017

As 2017 draws to a close, we look back at a year where advances in pharmaceutical drug therapies brought new hope to people from across the globe. These steps forward bring with them a sense of suspense as we wait for more ground-breaking work to be accomplished in 2018. Here is Drugdu.com’s list of medical advances that amazed.
- Source: Ddu
- 639
- December 25, 2017
Market Views pharmaceutical drugs
Tessa Therapeutics Closes USD 80 Million Financing Round Led by Temasek

Tessa Therapeutics, an international clinical stage biopharmaceutical company focusing on T cell therapy for solid tumors, announced the completion of a USD 80 million financing round led by Temasek, an investment company headquartered in Singapore, and joined by EDBI, Karst Peak Capital, Heliconia, Heritas and other investors.
- Source: Prnewswire
- 442
- December 22, 2017
cell Market Views tumor
Why Medical Device Cyber Threats Are Surging

Medical devices are increasingly the targets of cyber thieves looking to get their hands on sensitive information. And the risks are growing rapidly.
- Source: forbes
- 652
- December 21, 2017
healthcare Market Views medical device
Ultragenyx Sells Priority Review Voucher for $130 million

“The sale of the PRV provides us with an important source of non-dilutive capital to help advance our pipeline of rare and ultra-rare therapies, and accelerates the availability of these potential therapies to patients,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
- Source: finance.yahoo
- 715
- December 20, 2017
FDA Market Views Novartis PRV

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.